Pacira BioSciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Frank Lee

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	2.6yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO

Frank Lee (55 yo)

less than a year

Tenure

Mr. Frank D. Lee serves as Chief Executive Officer & Director at Pacira BioSciences, Inc. since January 02, 2024. He is the Executive Chairperson of the Board at Therini Bio, Inc. from May 2023. He has glo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charles Reinhart	Chief Financial Officer	8yrs	US$1.75m	0.046% $ 529.3k
Daryl Gaugler	Chief Operating Officer	2yrs	US$2.29m	0.015% $ 175.1k
Kristen Williams	Chief Administrative Officer & Secretary	9.6yrs	US$1.77m	0% $ 0
Anthony Molloy	Chief Legal & Compliance Officer	2.4yrs	US$2.05m	0.028% $ 316.8k
David Stack	Advisor	less than a year	US$6.85m	0.51% $ 5.8m
Frank Lee	CEO & Director	less than a year	no data	no data
Lauren Riker	Principal Accounting Officer & Senior VP of Finance	12.2yrs	US$288.82k	0.010% $ 114.1k
Susan Mesco	Head of Investor Relations	no data	no data	no data
Richard Kahr	Vice President of Human Resources	8.8yrs	no data	no data
Jonathan Slonin	Chief Medical Officer	2.8yrs	US$2.12m	0.040% $ 461.2k
Christopher Young	Chief Manufacturing Officer	1.1yrs	no data	no data

2.6yrs

Average Tenure

51yo

Average Age

Experienced Management: 82P's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Frank Lee	CEO & Director	less than a year	no data	no data
Laura Brege	Independent Director	12.9yrs	US$362.57k	0.021% $ 234.9k
Paul Hastings	Chairman of the Board	12.9yrs	US$383.57k	0.014% $ 162.3k
Gary Pace	Independent Director	15.9yrs	US$340.07k	0.044% $ 500.8k
Andreas Wicki	Independent Director	17.4yrs	no data	no data
Mark Kronenfeld	Independent Director	10.9yrs	US$360.33k	0.038% $ 440.4k
Christopher Christie	Independent Director	4.7yrs	US$325.07k	0.0075% $ 85.7k
Alethia Young	Independent Director	less than a year	no data	0% $ 0
Marcelo Bigal	Independent Director	less than a year	no data	0% $ 0
Abraham Ceesay	Independent Director	less than a year	no data	0% $ 0
Mark Froimson	Independent Director	6.9yrs	US$346.07k	0.013% $ 149.3k
Michael Yang	Independent Director	less than a year	no data	0% $ 0

5.8yrs

Average Tenure

62yo

Average Age

Experienced Board: 82P's board of directors are considered experienced (5.7 years average tenure).

Pacira BioSciences Management

Management criteria checks 2/4

Key information

Recent management updates

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Independent Director recently sold €3.3m worth of stock

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

High number of new directors

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Recent updates

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold €3.3m worth of stock

Full year 2023 earnings released: EPS: US$0.91 (vs US$0.35 in FY 2022)

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

High number of new directors

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: EPS: US$0.56 (vs US$0.44 in 2Q 2022)

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Chief Financial Officer recently sold €854k worth of stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings released: US$0.42 loss per share (vs US$0.15 profit in 1Q 2022)

Now 21% undervalued

Full year 2022 earnings released: EPS: US$0.35 (vs US$0.95 in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Insufficient new directors

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

Pacira Biosciences, Inc. Announces Positive Topline Data from Phase 3 Study of EXPAREL as A Single-Dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Pacira BioSciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacira Biosciences, Inc. Not to Provide Revenue Guidance for the Fiscal Year 2022

Chief Clinical Officer recently sold €52k worth of stock

Chairman & CEO recently sold €687k worth of stock

Independent Director recently sold €56k worth of stock

First quarter 2022 earnings released: EPS: US$0.15 (vs US$0.24 in 1Q 2021)

Insufficient new directors

Pacira BioSciences, Inc., Annual General Meeting, Jun 07, 2022

Pacira BioSciences, Inc. Provides Preliminary Revenue Guidance for the First Quarter of 2022

Insufficient new directors

Pacira BioSciences, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: EPS US$0.40 (vs US$3.03 in 3Q 2020)

Pacira BioSciences, Inc Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries

Second quarter 2021 earnings released: EPS US$0.43 (vs US$0.17 loss in 2Q 2020)

Insufficient new directors

Pacira Biosciences, Inc. Announces FDA Approval of Enhanced Exparel Manufacturing Process

Pacira BioSciences, Inc.(NasdaqGS:PCRX) dropped from Russell 2000 Growth-Defensive Index

Pacira BioSciences, Inc. Announces Top-Line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block

Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021

Pacira Biosciences, Inc. Announces That Product Sales Continue to Be Negatively Impacted by the Covid-19 Pandemic for the Full Year 2021

Full year 2020 earnings released: EPS US$3.41 (vs US$0.27 loss in FY 2019)

Revenue beats expectations

Pacira BioSciences, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €63.50

New 90-day high: €57.50

Investor sentiment improved over the past week

Pacira BioSciences, Inc. Receives European Commission Approval for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain

Market bids up stock over the past week

New 90-day low: €42.40

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain

An undisclosed buyer acquired an unknown stake in Pacira BioSciences, Inc. from Hercules Capital, Inc. (NYSE:HTGC).

Pacira BioSciences, Inc. Not to Provide Financial Guidance for the Full Year 2020

First half earnings released

Pacira BioSciences, Inc. to Report Q2, 2020 Results on Aug 06, 2020

CEO

Tenure

Leadership Team